Comparative Pharmacology
Head-to-head clinical analysis: ARISTOSPAN versus CORTIFOAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOSPAN versus CORTIFOAM.
ARISTOSPAN vs CORTIFOAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Triamcinolone hexacetonide (Aristospan) is administered intra-articularly or intralesionally. For intra-articular use in adults, typical dose is 2–20 mg (0.5–1 mL of 20 mg/mL suspension) depending on joint size. For intralesional use, 2–3 mg per injection site, with total dose not exceeding 0.5 mg/kg per day.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
None Documented
None Documented
Triamcinolone hexacetonide: terminal half-life approximately 2-3 weeks (88-144 hours) due to slow release from depot site; clinical effects persist for weeks to months.
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Primarily hepatic metabolism; renal excretion of inactive metabolites (<5% unchanged); minimal biliary/fecal excretion.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Category C
Category C
Corticosteroid
Corticosteroid